儿科异构性家族性高胆固醇血症中的埃沃洛库马布:在80周的开放性延长治疗期间的认知功能
Raul D Santos1, Andrea Ruzza2, Bei Wang3
1Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital and Hospital Israelita Albert Einstein, Av. Dr Enéas C. Aguiar 44, Sao Paulo 05403-900, Brazil.
European journal of preventive cardiology
|October 19, 2023
概括
在患有家族性高胆固醇血症 (FH) 的儿科患者中,80周的evolocumab治疗没有对认知功能产生负面影响. 这一发现支持该人群中PCSK9抑制的长期安全性.
科学领域:
- 心脏病学 心脏病学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 家族性高胆固醇血症 (FH) 是一种导致高LDL胆固醇的遗传性疾病.
- 像evolocumab这样的PCSK9抑制剂有效降低LDL-C,并且通常耐受良好.
- 之前的研究表明,在儿科FH患者短期使用evolocumab时,没有认知障碍.
研究的目的:
- 评估埃沃洛库马布对患有异合性FH的儿科患者认知功能的长期影响.
- 将认知安全的评估扩展到最初的24周HAUSER-RCT研究之外.
主要方法:
- 一个80周的开放标签延长 (HAUSER-OLE) 的HAUSER-RCT研究.
- 患有FH的儿科患者 (10-17岁) 每月接受皮下治疗的埃沃洛库马布 (420毫克).
- 在基线,24周和80周使用心理运动功能,注意力,视觉学习和执行功能测试来评估认知功能.
主要成果:
- 在80周的evolocumab治疗中,没有观察到认知表现的统计显著下降.
- 在所有认知任务的表现在接受安慰剂或evolocumab在母RCT中的患者中保持相似.
- 治疗对认知功能的影响大小是微不足道的 (科恩的d<0.2).
结论:
- 在儿科FH患者中,长达80周的evolocumab治疗没有对认知功能产生不良影响.
- 这些发现加强了FH青少年长期PCSK9抑制的认知安全概况.
关键词:
动脉样硬化心血管疾病.中枢神经系统中枢神经系统孩子 孩子 孩子 孩子低密度脂蛋白胆固醇是低密度的脂蛋白胆固醇.蛋白转化酶子素素9 (PCSK9) 是一种蛋白转化酶.安全的安全的安全的安全的安全.更多相关视频
10:56A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
8.2K
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.7K
相关概念视频
01:16Clinical Trials
6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.8K
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:26Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
131
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
131
01:19Pharmacovigilance
860
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
860
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
11
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
11